Scarica l'app Stockscreener
12.12
6.77%
-0.88
Precedente Chiudi:
$13.00
Aprire:
$12.74
Volume 24 ore:
93,000
Relative Volume:
0.01
Capitalizzazione di mercato:
$2.15M
Reddito:
$8.97M
Utile/perdita netta:
$-15.21M
Rapporto P/E:
-0.104
EPS:
-116.51
Flusso di cassa netto:
$-10.84M
1 W Prestazione:
-18.11%
1M Prestazione:
+4,651%
6M Prestazione:
+811.28%
1 anno Prestazione:
+384.80%
Intervallo 1D:
$11.58
$12.79
Intervallo di 1 settimana:
$11.58
$15.87
Portata 52W:
$0.19
$25.95
Nuwellis Inc Stock (NUWE) Company Profile
Nome
Nuwellis Inc
Settore
Industria
Telefono
952-345-4200
Indirizzo
12988 VALLEY VIEW ROAD, EDEN PRAIRIE
Confronta NUWE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUWE
Nuwellis Inc
|
12.12 | 2.15M | 8.97M | -15.21M | -10.84M | -116.51 |
|
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Nuwellis Inc Stock (NUWE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-29 | Iniziato | ROTH MKM | Buy |
Nuwellis Inc Borsa (NUWE) Ultime notizie
Is Nuwellis Inc. a good long term investmentSignificant capital appreciation - PrintWeekIndia
What drives Nuwellis Inc. stock priceExtraordinary performance - Autocar Professional
What analysts say about Nuwellis Inc. stockRecord-breaking gains - Autocar Professional
What makes Nuwellis Inc. stock attractive to long term investorsFree Trend-Following Techniques - jammulinksnews.com
What makes Nuwellis Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Nuwellis Regains Nasdaq Compliance After Delisting Risk - TipRanks
Nuwellis Regains Compliance to Trade on Nasdaq - MarketScreener
Nuwellis regains Nasdaq compliance as minimum bid price requirement met By Investing.com - Investing.com Nigeria
Nuwellis regains Nasdaq compliance as minimum bid price requirement met - Investing.com Australia
Nuwellis Participates in the Virtual Investor “What's Your Story - GuruFocus
Nuwellis Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - Yahoo Finance
Nuwellis Regains Compliance with Nasdaq Listing Requirements - The Manila Times
Nuwellis regains Nasdaq compliance, avoids delisting hearing - Investing.com Australia
Nuwellis regains compliance with Nasdaq listing requirements - TipRanks
Nuwellis, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Nasdaq
Nuwellis Secures Future on Nasdaq as Stock Meets Critical Trading Requirements - Stock Titan
Nuwellis Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - jammulinksnews.com
Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025 - The Manila Times
Nuwellis, Medical Fluid Management Leader, Sets Q2 2025 Earnings Call for August 12 - Stock Titan
Why Nuwellis Inc. stock attracts strong analyst attentionFree Consultation - Newser
Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant - MSN
Nuwellis Terminates REVERSE-HF Trial, Shifts Focus to Outpatient Heart Failure Care and Pediatric Markets - AInvest
Nuwellis Ends REVERSE-HF Trial to Focus on Growth Areas, Saves $4 Million - AInvest
Nuwellis ends clinical trial of its ultrafiltration tech for heart failure - MassDevice
Medical Stocks To Add to Your Watchlist – July 16th - Defense World
Nuwellis stock falls after company terminates REVERSE-HF clinical trial By Investing.com - Investing.com South Africa
Nuwellis stock falls after company terminates REVERSE-HF clinical trial - Investing.com
Nuwellis' New U.S. Patent and Market Implications: A Game-Changer in Fluid Management and a Long-Term Growth Catalyst for Investors - AInvest
Nuwellis terminates REVERSE-HF trial to focus on outpatient heart failure care - TipRanks
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care - The Manila Times
Nuwellis, Inc. Terminates REVERSE-HF Clinical Trial to Focus on Outpatient Market Opportunities - Nasdaq
Nuwellis Pivots from REVERSE-HF Trial: Strategic $4M Shift to Outpatient Heart Failure Care Revealed - Stock Titan
Nuwellis Plunges 11.29% After Patent Surge - AInvest
Biotech And Crypto Moves Set Off Trading Frenzy - Finimize
Nuwellis Surges to 137th in Market Rankings with $703 Million Trading Volume - AInvest
Nuwellis appoints John Erb as CEO - MSN
Nuwellis Secures Patent Leadership in CRRT: A Breakthrough in Fluid Management for Critical Care - AInvest
Medical Stocks To Add to Your WatchlistJuly 16th - MarketBeat
Nuwellis' Patent Breakthrough: Can Fluid Management Innovation Sustain Momentum? - AInvest
Nuwellis (NUWE) Stock Skyrockets On New Patent: What's Going On? - Benzinga
Nuwellis Inc Azioni (NUWE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):